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Pre-Existent Left Atrial Scarring in Patients
ndergoing Pulmonary Vein Antrum Isolation
n Independent Predictor of Procedural Failure
tul Verma, MD, Oussama M. Wazni, MD, Nassir F. Marrouche, MD, David O. Martin, MD,
ethi Kilicaslan, MD, Stephen Minor, MD, Robert A. Schweikert, MD, Walid Saliba, MD,
ennifer Cummings, MD, J. David Burkhardt, MD, Mandeep Bhargava, MD, William A. Belden, MD,
hmad Abdul-Karim, MD, Andrea Natale, MD
leveland, Ohio
OBJECTIVES The goal of this study was to assess the impact of left atrial scarring (LAS) on the outcome
of patients undergoing pulmonary vein antrum isolation (PVAI) for atrial fibrillation (AF).
BACKGROUND Left atrial scarring may be responsible for both the perpetuation and genesis of AF.
METHODS A total of 700 consecutive patients undergoing first-time PVAI were studied. Before ablation,
extensive voltage mapping of the left atrium (LA) was performed using a multipolar Lasso
catheter guided by intracardiac echocardiography (ICE). Patients with LAS were defined by
a complete absence of electrographic recording by a circular mapping catheter in multiple LA
locations, and this was validated by electroanatomic mapping. All four pulmonary vein antra
and the superior vena cava were isolated using an ICE-guided technique. Patients were
followed at least nine months for late AF recurrence. Univariate and multivariate analyses
were performed to assess the predictive value of LAS and other variables on outcome.
RESULTS Of 700 patients, 42 had LAS, which represented 21  11% of the LA surface area by
electroanatomic mapping. Patients with LAS had a significantly higher AF recurrence (57%)
compared with non-LAS patients (19%, p  0.003). Also, LAS was associated with a
significantly larger LA size, lower ejection fraction, and higher C-reactive protein levels.
Univariate analysis revealed age, nonparoxysmal AF, and LAS as predictors of recurrence.
Multivariate analysis showed LAS as the only independent predictor of recurrence (hazard
ratio 3.4, 95% confidence interval 1.3 to 9.4; p  0.01).
CONCLUSIONS Pre-existent LAS in patients undergoing PVAI for AF is a powerful, independent predictor
of procedural failure. Left atrial scarring is associated with a lower EF, larger LA size, and
increased inflammatory markers. (J Am Coll Cardiol 2005;45:285–92) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.035American College of Cardiology Foundation
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ilectrical and structural remodeling of the atrium occurs in
atients with atrial fibrillation (AF) and structural heart
isease (1). In particular, studies have demonstrated that
ome patients with atrial arrhythmias have spontaneous
trial scarring characterized by discrete regions of low
oltage (2). These changes in substrate may be responsible
or both the perpetuation and genesis of AF. The mecha-
ism for this scarring, as well as its relationship to clinical
utcome, is not well known.
Catheter ablation of AF using the technique of pulmo-
ary vein antrum isolation (PVAI) has emerged as an
ffective therapy for patients with symptomatic AF (3).
owever, although there have been numerous studies ex-
mining the predictors of AF recurrence after electrical
ardioversion or with antiarrhythmic therapy (4,5), little is
nown about predictors of recurrence after PVAI. Specifi-
ally, it is unknown whether the presence of atrial scarring
as any impact on post-PVAI outcome. Left atrial scarring
LAS) may serve as a substrate for slow conduction and
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leveland Clinic Foundation, Cleveland, Ohio. Dr. Verma is supported by a
ellowship award from the Heart and Stroke Foundation of Canada.w
Manuscript received June 14, 2004; revised manuscript received September 3, 2004,
ccepted October 4, 2004.ntra-atrial re-entry, which may predispose to future atrial
rrhythmia (6,7). Thus, the goals of this study were to
haracterize LAS and to assess its impact on the long-term
rocedural outcome in patients undergoing first-time PVAI
or treatment of AF.
ETHODS
tudy population. Consecutive patients presenting to our
nstitution for first-time PVAI for treatment of AF between
anuary 2002 and August 2003 were included in this study.
atients presenting for repeat PVAI or with a history of any
revious catheter ablation were excluded from the study.
atients with previous cardiac surgery were also excluded
rom the study. Patients selected for PVAI all had symp-
omatic AF, which was paroxysmal, persistent, or perma-
ent and refractory to two or more antiarrhythmic drugs. A
otal of 700 patients were identified and included in the
tudy. All patients gave written, informed consent before
he mapping and ablation procedures, and collection of
atient data was performed in accordance with institutional
thics guidelines.
VAI procedure. All patients underwent PVAI using an
ntracardiac echocardiography (ICE)-guided technique,
hich is summarized here but described in extensive detail
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Left Atrial Scarring and AF Ablation January 18, 2005:285–92lsewhere (3,8). After femoral venous access was obtained, a
0-F, 64-element, phased-array ultrasound imaging cathe-
er (Siemens AG, Malvern, Pennsylvania) was positioned in
he right atrium. Under ICE guidance, a decapolar circular
Lasso) mapping catheter and an 8-mm tip ablation catheter
Biosense Webster Inc., Diamond Bar, California) were
dvanced into the left atrium (LA) via two transseptal
unctures. The patient was systemically anticoagulated with
ntravenous heparin to maintain an activated clotting time
f 350 to 400 s. Then, ICE was used to define the
ulmonary venous antra and guide sequential placement of
he Lasso catheter in all positions surrounding (and outside
f) each pulmonary vein (PV). Radiofrequency ablation was
erformed wherever PV potentials were recorded around
he PV antra. The radiofrequency energy output was limited
o a maximum of 70W and 55 oc and was titrated according
o microbubble formation detected by ICE. The end point
f ablation was complete electrical disconnection of the PV
ntrum from the LA. This was considered achieved when
o PV potentials could be recorded along the antrum or
nside the vein by the Lasso during sinus rhythm or coronary
inus pacing. At the end of the procedure, all four pulmo-
ary venous antra were extensively remapped with the Lasso
o check for any persisting PV potentials, and if necessary,
urther ablation was performed to eliminate these. All four
Vs and the superior vena cava were isolated in every
atient. No ablation lines between the mitral annulus and
Vs were made.
A mapping and definition of scar. Before PVAI, all
atients underwent detailed voltage mapping of the LA.
apping was always performed in sinus rhythm whenever
ossible. For those patients in AF at the start of the
rocedure, external direct current cardioversion was per-
ormed to convert the patient to sinus rhythm to allow
apping. If necessary, more than one cardioversion was
erformed if AF recurred during mapping. In some patients
ith permanent AF who could not be cardioverted to sinus
or even a few beats before ablation, mapping had to be
erformed in AF.
Because we do not routinely use an electroanatomic
apping system for PVAI, voltage mapping was initially
erformed in all patients using the 20-mm diameter deca-
Abbreviations and Acronyms
AF  atrial fibrillation
BNP  B-type natriuretic peptide
CRP  C-reactive protein
EF  ejection fraction
EGM  bipolar electrogram
ICE  intracardiac echocardiogram
LA  left atrium
LAS  left atrial scarring
PV  pulmonary vein
PVAI  pulmonary vein antrum isolationolar circular (Lasso) mapping catheter. The catheter was rsed to map the entire LA, including the posterior wall,
nterior wall, and roof, while staying outside of the PVs.
oth ICE and fluoroscopy guided Lasso movement and
osition in the LA. Contact between the Lasso and atrial
urface was confirmed using ICE. Bipolar electrograms
EGMs) were recorded and filtered at 30 to 400 Hz.
rovided that the Lasso had good atrial contact, patients
ith LAS were identified by a complete absence of atrial
GMs seen in all 10 poles of the circular mapping catheter
n at least three distinct Lasso positions in the LA. In order
o validate our definition and more accurately quantify the
xtent of scarring, all patients in the LAS group enrolled
fter January 2003 had electroanatomic mapping of the LA
erformed using the CARTO system (Biosense Webster
nc.). For comparison, we also performed CARTO maps of
he LA in a subset of consecutive patients in the non-LAS
roup (some of these CARTO maps were also performed as
art of another study). Mapping was performed with a
-mm-tip catheter (Navistar, Biosense Webster Inc.). For
ARTO mapping, “scar” was defined as an absence of
oltage or a bipolar voltage amplitude 0.05 mV indistin-
uishable from noise; low-voltage “abnormal” areas were
efined as an amplitude 0.5 mV, as reported elsewhere
2,9). The CARTO system is able to measure the distance
etween any two points. Using the assumption that a
carred segment of LA could be divided into multiple
maller rectangular or trapezoidal shapes, the area of the
egment could be approximated by summing the areas of the
maller shapes. This segment was then expressed as a
ercentage of the total approximated LA surface area
assessed by the same technique) excluding the tubular
ortion of the PVs. A similar technique has been previously
eported for mapping the left ventricle (10).
iochemical markers. All patients had serum drawn just
efore PVAI for assessment of C-reactive protein (CRP)
nd brain natriuretic peptide (BNP) levels. The CRP levels
ere assayed by immunonephelometry using the Dade
ehring BNIII analyzer protocol (Dade Behring, Deerfield,
llinois). The BNP levels were determined using the assay
y Biosite Diagnostics (San Diego, California).
ollow-up. After the procedure, patients continued anti-
oagulation with warfarin to maintain an international
ormalized ratio of 2.0 to 3.0 for a minimum of three
onths. In all patients, antiarrhythmic medications were
ontinued for two months after ablation and were chosen
rom one of sotalol, propafenone, flecainide, or dofetilide.
miodarone was not used after ablation. Antiarrhythmic
edications were discontinued in all patients after two
onths.
Late recurrence of AF was defined as AF occurring
eyond two months after PVAI. Thus, success was defined
s a lack of late AF recurrence off antiarrhythmic medica-
ion. All patients included in this study were followed up for
minimum of nine months after ablation and successfully
nderwent our follow-up procedures. All patients wore
hythm transmitters for a minimum of three months after
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January 18, 2005:285–92 Left Atrial Scarring and AF AblationVAI, and this was extended by another three months for
atients with early AF recurrences. Patients had scheduled
linical visits, 12-lead electrocardiography (ECG), and 48-h
olter monitoring at 3, 6, and 12 months after ablation.
nterrogation of implanted devices was also used (when
vailable) to confirm arrhythmia recurrence. Patients were
lso advised to report any recurrence of symptoms to the
linic, at which point, 48-h Holter monitoring was per-
ormed. Recurrences were based on patient reporting,
hythm transmitter, and Holter and/or ECG data. Spiral
omputed tomography was performed about three months
fter ablation in all patients to assess for PV stenosis. The
ean follow-up time for all patients in this study was
5.8  7.8 months.
tatistical analysis. All data are reported as the mean value
SD, unless otherwise indicated. A collection of the
haracteristics of patients with and without LAS and
nivariate analysis to assess the predictive value of clinical
ariables on AF recurrence was performed using the un-
aired, independent samples t test for continuous variables,
nd the chi-square test for categorical variables. Multivariate
nalysis was performed using Cox regression analysis, with
determination of a hazard ratio and its 95% confidence
nterval (CI) for each variable in the model. Survival curves
escribing freedom from AF in LAS and non-LAS patients
ere determined using the Kaplan-Meier method. Survival
urves were compared using the log-rank test. A p value of
0.05 was considered significant for all statistical determi-
ations. All analyses were performed using SPSS software
ersion 11.0 (SPSS, Chicago, Illinois).
ESULTS
atient characteristics with and without LAS. Of the
00 patients included in the study, 42 (6%) had LAS, as
efined in the Methods section. The characteristics of the
atients with and without LAS are listed in Table 1. A
trong trend was observed in which a lower proportion of
able 1. Characteristics of Patients With and Without Left
trial Scarring
LA Scar
(n  42)
No LA Scar
(n  658) p Value
ge (yrs) 59 13 53  13 0.09
aroxysmal AF (n) 11 (26%) 263 (40%) 0.07
F duration (yrs) 7.0 4.9 6.1  5.4 0.39
tructural heart disease (n) 20 (48%) 289 (44%) 0.72
A size (cm) 4.9  0.7 4.0  0.8 0.03*
jection fraction (%) 49 8% 54  7% 0.03*
-reactive protein (mg/l) 5.93  7.75 0.31  0.68 0.01*
rain natriuretic peptide
(pg/ml)
191  92 110  80 0.06
rocedure time (min) 168 47 162  40 0.27
F time (min) 47  25 45  28 0.48
F recurrence (n) 24 (57%) 128 (19%) 0.003*
Significant value (p  0.05). Data are presented as the mean value  SD or number
%) of patients.
AF  atrial fibrillation; LA  left atrial; RF  radiofrequency.atients with LAS presented with paroxysmal AF (11 t26%] of 42) compared with those without LAS (263
40%] of 658), but this difference was not quite statisti-
ally significant (p  0.07). Patients with LAS had a
ignificantly larger LA size compared with patients with-
ut LAS, with mean values of 4.9  0.7 cm and 4.00.8
m, respectively (p  0.03). The mean ejection fraction
EF) was also lower in patients with LAS compared with
atients without it, with mean values of 49  8% and 54
7%, respectively (p  0.03).
Late recurrence of AF after PVAI (beyond two months)
as significantly higher in patients with LAS (24 [57%] of
2) compared with patients without LAS (128 [19%] of
58; p  0.003). Kaplan-Meier curves describing late AF
ecurrence in patients with and without LAS are depicted in
igure 1. The mean time to late recurrence for patients with
AS was 101  49 days versus 133  40 days for patients
ithout LAS (p  0.17). Of the patients who recurred, 17
f 24 in the LAS group and 117 of 128 in the non-LAS
roup underwent a second procedure. After this second
rocedure, 3 (18%) of 17 LAS patients and 57 (49%) of 117
on-LAS patients remained free of AF. Using these second
rocedure success rates and assuming that all patients with
ecurrence underwent a second PVAI, the overall cure rate
fter two procedures would have been 52% in LAS patients
nd 90% in non-LAS patients.
As indicated in Table 1, the mean age, AF duration, and
ncidence of structural heart disease (any hypertensive,
oronary, valvular, or cardiomyopathic disease) were no
ifferent in the two groups (p  NS for all). Isolation of all
our PV antra was achieved in all of the patients in both
AS and non-LAS groups at the end of the ablation
rocedure (as described in the Methods section). Procedure
ime and total radiofrequency time did not differ between
igure 1. Kaplan-Meier curves depicting late atrial fibrillation (AF)
ecurrence in patients with and without left atrial scarring (LAS) over time.
atients with LAS have a significantly increased incidence of late AF
ecurrence compared with patients without LAS (p  0.01 by log-rank).he groups (Table 1).
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Left Atrial Scarring and AF Ablation January 18, 2005:285–92iochemical markers with and without LAS. The CRP
nd BNP results for patients with and without scar are
ompared in Table 1. The CRP levels were significantly
igher in patients with LAS compared with patients with-
ut it. The LAS patients had a mean CRP level of 5.93 
.75 mg/l, as compared with 0.31  0.68 mg/l in patients
ithout LAS (p  0.01). There was a strong trend toward
igher BNP levels in patients with LAS, but this did not
each statistical significance. The mean BNP level was
91  92 pg/ml in LAS patients compared with 110  80
g/ml in non-LAS patients (p  0.06). The mean serum
reatinine was no different between the LAS and non-LAS
roups (1.1  0.3 vs. 1.2  0.4 mg/dl, p  0.51). The
ercentage of patients taking statins and angiotensin-
onverting enzyme inhibitors also did not differ between the
wo groups (p  NS for both).
lectroanatomic mapping of LAS. Of the 42 patients
ith LAS included in the study, 19 underwent electroana-
omic mapping with CARTO. A total of 115 consecutive
ARTO maps were performed in patients without LAS. A
ean of 164  68 points was acquired for each map.
apping had to be performed in AF for 2 (10%) of 19 and
(7%) of 115 of LAS and non-LAS patients, respectively.
he presence of multiple, large regions of scar (as defined
igure 2. Representative three-dimensional electroanatomic voltage map (C
ray regions indicate areas of electrical silence (scar). Red regions indicat
his case, scarred and abnormal regions constitute almost two-thirds of th
ssociated branches.arlier) was confirmed in all of the CARTO maps for LAS ratients. Scar covered an average of 21  11% of the
stimated LA surface area. In LAS patients, scar was also
ssociated with extensive low-voltage regions. A represen-
ative example of a CARTO voltage map in a patient with
AS is shown in Figure 2. In contrast, very small, isolated
egions of scar were identified in only 6 (5%) of 115
on-LAS patients, covering5% of the estimated LA area.
his small subset did not significantly differ in clinical
haracteristics from the rest of the non-LAS group. Mean
oltage in LAS patients was 1.3  0.4 mV compared with
.1  0.6 mV in non-LAS patients (p  0.02). When the
oltage data from patients in refractory AF are excluded,
ean voltage in LAS patients was 1.4  0.4 mV, as
ompared with 2.2  0.7 mV in non-LAS patients (p 
.03).
nivariate predictors of late AF recurrence. Univariate
redictors of late AF recurrence are detailed in Table 2.
here were a total of 152 recurrences in the total population
f 700 patients. Of the variables analyzed, only the presence
f LAS, age, and nonparoxysmal AF were found to be
ignificant predictors of late AF recurrence. The presence of
AS was the most significant of the univariate predictors.
wenty-four (16%) of 152 patients with recurrence had
AS, as compared with 18 (3%) of 548 of patients without
O) depicting left atrial scarring (LAS) in a patient included in this study.
s of abnormal atrial endocardium as defined by a voltage of 0.5 mV. In
al surface. The colored tube structures represent the four PVs and theirART
e areaecurrence (p  0.002). Patients with recurrence were older
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ears; p  0.01). More patients with recurrence also had
onparoxysmal AF (persistent or permanent), as compared
ith those without recurrence (75% vs. 57%, p  0.047).
ther variables, including LA size, EF, gender, AF dura-
ion, and number of antiarrhythmic medications that failed,
ere not significantly different in the recurrence and non-
ecurrence groups. We did not find a significant difference
n CRP or BNP levels in patients with and without
ecurrence.
The same univariate predictors were found to be signif-
cant in the subset of patients with CARTO maps as for the
ntire cohort.
ultivariate predictors of late AF recurrence. Multivari-
te predictors of late AF recurrence are depicted in Figure 3.
nly the presence of LAS was a significant independent
able 2. Univariate Predictors of Late Atrial Fibrillation
ecurrence
Recurrence
(n  152)
No Recurrence
(n  548) p Value
car (n) 24 (16%) 18 (3%) 0.002*
ge (yrs) 61 14 52 11 0.01*
onparoxysmal AF (n) 114 (75%) 312 (57%) 0.047*
ale gender (n) 111 (73%) 434 (79%) 0.24
F duration (yrs) 6.5 6.1 6.3 5.4 0.90
ntiarrhythmic drugs failed
(n)
2.1 1.4 2.2 1.0 0.75
tructural heart disease (n) 78 (51%) 231 (42%) 0.09
A size (cm) 4.4 0.7 4.1 0.8 0.10
jection fraction (%) 53 8% 52 8% 0.88
-reactive protein (mg/l) 0.99 3.21 0.68 2.84 0.67
rain natriuretic peptide
(pg/ml)
125 140 112 152 0.52
Significant value (p  0.05). Data are presented as the number (%) of patients or
ean value  SD.
Abbreviations as in Table 1.
igure 3. Multivariate predictors of late atrial fibrillation (AF) recurrence a
oints, and the 95% confidence interval (CI) is indicated by the solid horiz
LA) scarring was found to be an independent predictor, with a hazard ratio of
isease.redictor of late AF recurrence when combined with other
linical variables in Cox regression modeling. The hazard ratio
or recurrence in patients with LAS was 3.4 (95% CI 1.3 to
.4, p 0.01). Age and nonparoxysmal AF were not found to
e significant independent predictors. The hazard ratio for age
per decade) was 1.33 (95% CI 0.86 to 2.10, p  0.21); for
onparoxysmal AF, it was 1.57 (95% CI 0.80 to 2.68, p 
.18).
ISCUSSION
ain findings. This study describes an important risk
actor for AF recurrence in patients who have undergone
F catheter ablation. In patients undergoing PVAI for AF,
AS is a powerful, independent predictor of long-term
ecurrence after the procedure. In fact, using multivariate
nalysis, LAS was the only variable that significantly pre-
icted post-PVAI AF recurrence. Not only is LAS associ-
ted with a higher AF recurrence rate, but it is also
ssociated with a larger left atrial size, lower EF, and higher
evels of both CRP and BNP. Left atrial scarring detected
y contact voltage mapping with a multipolar circular
atheter also correlates to substantial surface areas of scar
nd abnormal atrium, as detected by three-dimensional
lectroanatomic mapping. This study presents quite a large
ohort of PVAI patients to systematically examine the risk
actors for AF recurrence after the procedure. It also
niquely identifies scarring in the LA as a risk factor for AF
ecurrence in the post-PVAI population.
Because our PVAI technique and that of many others do
ot routinely use electroanatomic mapping, we initially
dentified LAS patients using a Lasso catheter. An absence
f EGM was chosen for an objective definition that is easily
eproducible and applicable in both sinus rhythm and AF.
he observation that CARTO mapping confirmed the
ssed by Cox regression analysis. Hazard ratios are indicated by the square
l lines. P values for each variable are indicated at the right. Only left atrials asse
onta3.4 (95% CI 1.3 to 9.4, p  0.01). EF  ejection fraction; HD  heart
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Left Atrial Scarring and AF Ablation January 18, 2005:285–92resence of extensive scar versus none/minimal in LAS
ersus non-LAS patients, respectively, validates our method
f defining LAS patients.
Very small, isolated scar was found in a small minority of
on-LAS patients. This is not surprising given that scarring
ay be a prevalent phenomenon. The fact that this group
id not differ significantly from the rest of the non-LAS
ohort suggests that only patients with a larger scar burden
re at risk of procedural failure.
elationship of LAS to other AF predictors. Several of
he risk factors for AF recurrence that we identified have
een reported in other clinical settings. Age, EF, nonpar-
xysmal AF, and LA size have all been shown to predict AF
ecurrence after cardioversion and in other clinical settings
4,5,11,12). In the only other large series of AF ablation
atients, only LA size was shown to be a univariate
redictor of post-ablation recurrence in permanent AF
atients (13). However, we found that when combined with
AS in a multivariate model, none of these variables was an
ndependent predictor of recurrence. That is because we
emonstrated that nonparoxysmal AF, lower EF, and larger
A size were all related to LAS. Patients with LAS also
rended toward being older. By combining several features
hat are known to predict AF recurrence, LAS becomes a
ery powerful predictor. Left atrial scarring may be the final
ink that characterizes a population at highest risk of
ecurrence after PVAI.
elationship of LAS to recurrence. From our data, we
annot conclude whether LAS is the direct cause of AF
ecurrence or whether it is an associated condition. How-
ver, our findings are consistent with other studies that have
eported on the association between scarring and AF.
ncreased amounts of atrial fibrosis are found in the atria of
F patients (14) and have been directly implicated as a
ause of increased AF prevalence in postoperative patients
7). This is because scarring is likely an important etiologic
actor in AF persistence. Chronic atrial fibrosis and scarring
lter intraatrial conduction and increase atrial effective
efractory periods (2,6). Altered conduction and barriers
ormed by the scar may form the critical circuits for
ntra-atrial re-entry that promote AF persistence. Indeed,
trial fibrosis may be more important than electrical sub-
trate changes for the maintenance of AF (15,16).
By altering the atrial substrate, scarring may increase
ulnerability to AF induction by sources apart from the PV
ntral area. Ectopy beyond the PV region less commonly
riggers AF (17), perhaps because of longer coupling inter-
als and reduced firing frequency (18), which cannot easily
nduce AF in normal tissue. This explains why isolation of
he PV antra is curative of AF in 80% to 90% of patients.
owever, atrial fibrosis can lead to AF induction by burst or
remature atrial pacing that otherwise fails to cause AF in
ormal hearts (19,20). Scar may also predispose patients to
eft atrial flutters caused by left or right atrial triggers, which
n turn may degenerate into AF. Even the incidence of
on-PV region sources may be higher with fibrosis. Myo- tathic atrial cells can demonstrate abnormal triggered ac-
ivity (21,22), and atrial remodeling can increase the rate
nd organization of depolarization waves emanating from
ocal sources, promoting formation of intraatrial rotors (23).
hus, it is very plausible that the LAS directly contributes
o PVAI failure.
Scarring did not lead to procedural failure because of an
nability to achieve the end point of PV isolation. The
rocedures were not technically more demanding in scar
atients, with durations and fluoroscopy times very similar
o those of nonscar patients. If anything, patients with scar
resenting for their first or second ablation had fewer PV
otentials than those without scar, which is not surprising
iven that these patients have much less electrically active
issue to begin with.
The possibility that LAS is simply an associated “by-
tander” in patients with AF recurrence must also be
onsidered. Atrial fibrillation itself causes structural changes
ithin the atrium (24), so LAS may simply reflect preex-
sting AF burden. Furthermore, we do not know the exact
athologic correlate of LA scar. Although fibrosis is most
ikely, other substrates cannot be ruled out. Atrial amyloid,
or example, may be a stronger predictor of AF than fibrosis
25).
tiology of LAS. Several mechanisms have been impli-
ated in the formation of scar in the atrium. Chronic AF
tself may result in structural remodeling (24). Patients with
HF may develop diffuse fibrotic changes in the atrium
econdary to a pan-myocardial remodeling effect (2). How-
ver, there is an increasing amount of data showing that
nflammatory mediators and vasoactive peptides may play a
ey causative role in atrial structural remodeling (26,27).
Therefore, it is intriguing that we observed a higher mean
RP level in patients with LAS. This is consistent with
ther data demonstrating an association between CRP and
he risk of future AF (28) and failure of cardioversion for
F (29). It is possible that elevated CRP levels represent a
ro-inflammatory state that is directly responsible for atrial
car formation. Inflammation may directly cause atrial
brosis via oxidative damage (26). Furthermore, therapies
hat reduce CRP levels, such as statins, can decrease
tructural changes and AF burden in animal models (30).
owever, whether elevations in CRP are causative or simply
marker of atrial remodeling cannot be definitively deter-
ined by our data.
Levels of BNP were also higher in patients with LAS,
lthough this difference barely missed being statistically
ignificant (p 0.06). Brain natriuretic peptide is associated
ith worsening cardiac function and is prognostic of car-
iovascular events (31). However, it too may play a direct
ole in cardiac remodeling, along with other peptides such as
ngiotensin II (27). Our data thus present novel clinical
ssociations that may form the basis for further study into
he etiology of atrial scar formation.
linical implications. By identifying patients with LAS at
he time of PVAI, operators can immediately predict a high
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January 18, 2005:285–92 Left Atrial Scarring and AF Ablationhance of procedural failure. Based on this finding, it may be
ossible to alter therapy in this select group to maximize
uccess. Patients with LAS may require routine detailed
apping of the scar with ablation of all potential isthmuses
hat can cause intra-atrial re-entry to minimize recurrence.
second procedure does not appreciably increase the cure
ate, so perhaps repeat PVAI should not be routinely
ffered. The goal of total freedom from antiarrhythmic
herapy may also need to be revised in this group, and
ombination ablation with long-term drug therapy may be
he most effective approach. Finally, adjuvant therapy with
tatins and/or angiotensin-converting enzyme inhibitors
n LAS patients may prove promising in helping to limit
nd perhaps reverse scar formation and AF burden
30,32).
tudy limitations. The overall success rates reported in the
on-LAS patients here are somewhat lower than but
onsistent with recent reports by our group. We report one-
nd two-procedure success rates of 81% and 90%, respec-
ively, versus 83% to 85% and 93% to 98% by Khaykin et al.
8). The high end of the success rates in their report
epresents patients with purely lone AF, as opposed to this
on-LAS cohort, which is a heterogeneous group with
tructural heart disease. Furthermore, our current report
ncludes patients treated by multiple operators (currently
ve) in contrast to previous reports where one operator was
redominantly doing PVAI.
Furthermore, LAS is a risk factor that can only be
etermined invasively at the time of the procedure. Left
trial scarring cannot be used to preempt PVAI in patients
t very high risk of recurrence. It would be ideal if a
ombination of clinical variables, ECG criteria, and a
oninvasive imaging technique could predict scar before
VAI.
The prevalence of scar reported in our “control” group
ay be lower than expected. This may reflect a selection
ias given that fewer than one-half the patients had struc-
ural heart disease, and the majority had preserved EF. Also,
ur definition of scar is based on voltage mapping alone and
ot on the ability to capture at high-output pacing. Al-
hough this may be a limitation, the definition of scar using
oltage alone has been validated (33) and used extensively in
revious studies (2,10). It may also be technically challeng-
ng to access and maintain good contact with the Lasso in
ome parts of the LA, particularly the septal aspect of the
nterior wall. However, these areas do not represent large
ortions of the LA, and despite the challenges, we have
een able to map these regions consistently in patients.
inally, the length of follow-up and biases inherent to
ohort studies may limit our conclusions. However, our
ost-PVAI cohort represents one of the longer follow-up
urations published to date.
onclusions. Pre-existent LAS in patients undergoing
VAI for AF is a powerful, independent predictor of
rocedural failure. Left atrial scarring is associated with a
ower EF, larger LA size, and increased inflammatoryarkers. This study serves as a basis for further investigation
nto the cause of LAS and its exact relationship to AF
ecurrence.
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